Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) released its earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04, Zacks reports.
Oramed Pharmaceuticals Stock Down 0.5 %
Shares of Oramed Pharmaceuticals stock traded down $0.01 during trading on Tuesday, reaching $2.13. The company's stock had a trading volume of 91,211 shares, compared to its average volume of 157,143. The business has a 50 day moving average price of $2.29 and a 200-day moving average price of $2.35. Oramed Pharmaceuticals has a 12-month low of $1.96 and a 12-month high of $3.09. The company has a market capitalization of $85.86 million, a P/E ratio of 19.36 and a beta of 1.61.
Analysts Set New Price Targets
Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, February 19th.
Read Our Latest Stock Analysis on ORMP
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
